Creating a therapy to combat protein issues in neurodegenerative diseases
Developing an Anti-proteotoxicity Therapy for Neurodegenerative Diseases
['FUNDING_OTHER'] · REZIGENE, LLC · NIH-10920047
This study is looking at how problems with proteins in the brain might lead to diseases like Alzheimer's and ALS, and it's trying to find new ways to help our cells better handle these issues, which could lead to better treatments for these tough conditions.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | REZIGENE, LLC (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-10920047 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how protein misfolding and aggregation contribute to neurodegenerative diseases like Alzheimer's and ALS. By using advanced biochemical and genetic techniques, the team aims to identify new molecular targets and develop small molecule compounds that can enhance the cell's ability to manage protein quality control. The goal is to find innovative strategies to prevent and treat these debilitating conditions by harnessing the body's natural defense mechanisms against protein-related stress.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Alzheimer's disease, frontotemporal dementia, or amyotrophic lateral sclerosis.
Not a fit: Patients with neurodegenerative diseases not related to protein misfolding or aggregation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve the treatment of neurodegenerative diseases, potentially slowing their progression or alleviating symptoms.
How similar studies have performed: Previous research has shown promise in targeting protein quality control mechanisms, indicating that this approach could yield significant advancements in treating neurodegenerative diseases.
Where this research is happening
BALTIMORE, UNITED STATES
- REZIGENE, LLC — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHANG, TAO — REZIGENE, LLC
- Study coordinator: ZHANG, TAO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease, Amyotrophic Lateral Sclerosis Motor Neuron Disease